Michael Angelides is managing shareholder of Simmons Hanly Conroy, overseeing the firm’s asbestos, toxic tort, pharmaceutical injury, intellectual property infringement and contingent-fee commercial litigation practices.

Since joining the firm, Mike has continued to grow the firm’s reputation as a national leader in asbestos litigation, representing victims of mesothelioma against some of the largest companies in the nation.

As a leader in asbestos litigation, Mike has presented at both of the profession’s leading asbestos litigation conferences, Mealey’s and PALS. He has seen the firm expand from 7 to almost 70 attorneys and grown to accept more asbestos cases on an annual basis than any other firm in the country. Yet, through a proven business method, those cases receive dedicated individual attention unavailable at most firms.

“I’m proud of the fact that no one helps as many mesothelioma victims as the firm does on an annual basis,” Mike said.

He has also been instrumental in the growth of the firm’s pharmaceutical injury, intellectual property and commercial litigation practices. The firm now holds national litigation leadership positions related to the Yaz/Yasmin birth control recall, the popular smoking cessation drug Chantix and the DePuy ASR hip implant recalls. The firm’s pharmaceutical attorneys have recovered millions of dollars on behalf of consumers throughout the country who were injured due to dangerous drugs and defective medical devices.

In 2010, the firm’s commercial litigation department demonstrated the benefit of contingent-fee arrangements in commercial cases when it successfully negotiated a resolution for over 30 million dollars in an antitrust case. The victory garnered national media attention including publication in Forbes Magazine.